New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
10:45 EDTTWTR, MACK, EXPE, PEIX, WTWOptions with decreasing implied volatility: MACK WTW EXPE TWTR PEIX
News For MACK;WTW;EXPE;TWTR;PEIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 23, 2015
16:01 EDTTWTROptions Update; April 23, 2015
Subscribe for More Information
14:20 EDTTWTREarnings Watch: Google up close to 8.5% since last earnings report
Subscribe for More Information
12:38 EDTTWTRTwitter announces Highlights
Subscribe for More Information
11:41 EDTTWTRStocks with call strike movement; TWTR PBR
Subscribe for More Information
09:35 EDTTWTRActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FB PBR TWTR AA COST TSLA AMZN TXN BAC
07:25 EDTTWTRTwitter invests in becaon marketing startup Swirl, Re/code
Beacon marketing startup Swirl has raised $18M in its latest funding round, Re/code reports. The round was lead by Heart Ventures and includes SoftBank Capital (SFTBF) and Twitter Ventures (TWTR), Swirl CEO Hilmi Ozguc says. Reference Link
April 22, 2015
13:34 EDTTWTRTwitter top execs end programattic selling, Fortune says
Subscribe for More Information
11:25 EDTTWTRStocks with call strike movement; TWTR CREE
Twitter (TWTR) September 60 call option implied volatility increased 3% to 42, Cree (CREE) August 37.5 call option implied volatility decreased 11% to 34 according to IVolatility.
April 21, 2015
16:00 EDTTWTROptions Update; April 21, 2015
iPath S&P 500 VIX Short-Term Futures down 1c to 21.53 Option volume leaders: AAPL TSLA TWTR GILD FB PBR AMZN C KMI KO VZ MCD according to Track Data.
09:37 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:22 EDTMACKOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTMACKMerrimack to present updated clinical data from Phase 1 study of MM-141
Merrimack Pharmaceuticals announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors.
06:01 EDTMACKMerrimack price target raised to $16 from $13 at Mizuho
Subscribe for More Information
05:55 EDTTWTRTwitter starts selling tickets to sporting events, Re/code reports
Subscribe for More Information
April 20, 2015
16:07 EDTMACKMerrimack announces final clinical results for MM-302 Phase 1 study
Merrimack Pharmaceuticals announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer. Results from the trial showed that the group of patients treated with 30 mg/m2 or more of MM-302 alone, in combination with trastuzumab or with trastuzumab and cyclophosphamide, had a median progression free survival, or mPFS, of 7.6 months and an overall response rate, or ORR, of 11%. Of note, 25 patients who had not been previously treated with anthracyclines had an mPFS of 11 months and an ORR of 24%. The most frequent adverse events occurring in greater than 20% of the population in this Phase 1 study were constipation, cough, decreased appetite, diarrhea, dyspnea, fatigue, nausea, neutropenia, stomatitis and vomiting. The most common Grade 3/4 adverse event was neutropenia observed in 8 patients. Six out of 69 patients 9% had protocol-defined asymptomatic declines in left ventricular ejection fraction, or LVEF. In 1 of the 6 patients, this was reported as a Grade 1 cardiac failure that was possibly related to study treatment. Merrimack is currently enrolling the HERMIONE study that is designed to support a potential application for accelerated approval in the U.S. and conditional marketing authorization in the E.U. The HERMIONE study is for HER2-positive, metastatic breast cancer patients who are anthracycline-naive and have not been previously treated with pertuzumab and T-DM1-containing regimens.
16:01 EDTTWTROptions Update; April 20, 2015
iPath S&P 500 VIX Short-Term Futures down 78c to 21.52. Option volume leaders: AAPL VZ PBR TWTR TSLA TWTR NFLX MCP FB AMZN AA C according to Track Data.
12:59 EDTTWTRTwitter revamps Direct Messaging
In a blog post Twitter said: "Direct Messages are the best way to take your public Twitter conversations private. Today, weíre changing how direct messaging works so that itís even easier for you to communicate one-to-one or with a chosen group of people, anywhere in the world." Changes include: A setting that allows you to receive Direct Messages from anyone, even if you donít follow them. Updated messaging rules so you can reply to anyone who sends you a Direct Message, regardless of whether or not that person follows you. A new Direct Message button on profile pages on Android and iPhone. Youíll see it on the profiles of people you can send Direct Messages to. Reference Link
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
07:20 EDTMACKAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:19 EDTTWTRTwitter remains under-owned into Q1 results, says Deutsche Bank
Deutsche Bank says that while the set-up for shares of Twitter into the Q1 earnings report isn't as favorable as last quarter, the stock remains under-owned relative to most large cap Internet stocks. Deutsche notes its channel checks on Twitter have been "solid" all quarter around improving monetization trends. The firm sees "plenty" more upside for shares of Twitter and keeps a Buy rating on the name with a $65 price target.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use